A Central Biomarker for Synucleinopathies
α-Synuclein (α-Syn) plays a central role in the pathology of Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and related synucleinopathies. As a key component of Lewy bodies and Lewy neurites, α-syn aggregation and dysregulation are closely associated with neuronal dysfunction and neurodegeneration.
Fluid-based measurement of α-synuclein is increasingly used in translational biomarker research to investigate disease mechanisms, compare disease versus control populations, and monitor changes over time. Reliable quantification across multiple biofluids is critical for advancing these efforts.
Ultra-Sensitive Detection with SPEAR UltraDetect™
The SPEAR UltraDetect™ α-syn assay delivers high analytical performance for quantitative biomarker measurement.
Key analytical features include:
-
Femtogram sensitivity with ~2 fg/mL LOD
-
High precision with average CV < 5%
-
5-log dynamic range enabling reliable quantification across healthy and disease samples
-
100% quantifiability in healthy samples across verified matrices
-
Verified performance in CSF, EDTA plasma, and serum
This combination of sensitivity and precision supports both cross-sectional comparisons and longitudinal monitoring of α-synuclein levels.
Minimal Sample Input. Maximum Performance.
The homogeneous, wash-free SPEAR UltraDetect™ workflow requires only 1 µL of diluted sample per replicate, preserving precious biofluid samples while enabling scalable biomarker studies.
The semi-automated workflow requires less than 30 minutes of hands-on setup, supporting high-throughput experiments and longitudinal research across large study cohorts.
Assay Specifications
EDTA Plasma
| MRD | 4X |
| Diluted Sample Volume | 1 µL |
| Raw Sample Volume to Machine | 10 µL |
| LOD (pg/mL) | 0.002 |
| fLLOQ (pg/mL) | 0.078 |
| Spike-recovery (% recovery) | 121% |
| Linearity (% recovery) | 88.5% |
| Intra-plate CV (AVG %) | 3.4% |
| Inter-plate CV (AVG %) | 4.6% |
| EDTA Plasma Quantifiability | 100% |
